ווטריינט 200 מ"ג

Valsts: Izraēla

Valoda: ivrits

Klimata pārmaiņas: Ministry of Health

Aktīvā sastāvdaļa:

PAZOPANIB AS HYDROCHLORIDE 200 MG

Pieejams no:

GLAXO SMITH KLINE (ISRAEL) LTD

ATĶ kods:

L01XE11

Zāļu forma:

FILM COATED TABLETS

Ievadīšanas:

PER OS

Ražojis:

GLAXO OPERATIONS UK LIMITED

Ārstniecības grupa:

PAZOPANIB

Ārstēšanas norādes:

Renal cell carcinoma (RCC)Votrient is indicated in adults for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.Soft tissue sarcoma (STS)Votrient is indicated for the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

Autorizācija datums:

2011-01-01